US 12325755
Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
granted A61KA61K2039/505A61K31/7088
Quick answer
US patent 12325755 (Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics) held by The Regents of the University of California expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 43
- CPC classes
- A61K, A61K2039/505, A61K31/7088, A61K47/6811, A61K47/6817